Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Yuthavong, Yongyuth, Tarnchompoo, Bongkoch, Vilaivan, Tirayut, Chitnumsub, Penchit, Kamchonwongpaisan, Sumalee, Charman, Susan A., McLennan, Danielle N., White, Karen L., Vivas, Livia, Bongard, Emily, Thongphanchang, Chawanee, Taweechai, Supannee, Vanichtanankul, Jarunee, Rattanajak, Roonglawan, Arwon, Uthai, Fantauzzi, Pascal, Yuvaniyama, Jirundon, Charman, William N., Matthews, David
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2012
Teme:
Biological Sciences
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3479511/
https://ncbi.nlm.nih.gov/pubmed/23035243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1204556109
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki